Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Operating Expenses: 2021-2025

Historic Operating Expenses for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $90.7 million.

  • Arcutis Biotherapeutics' Operating Expenses rose 8.20% to $90.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.2 million, marking a year-over-year increase of 11.08%. This contributed to the annual value of $324.9 million for FY2024, which is 8.06% up from last year.
  • Arcutis Biotherapeutics' Operating Expenses amounted to $90.7 million in Q3 2025, which was down 5.64% from $96.1 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Operating Expenses ranged from a high of $105.5 million in Q3 2022 and a low of $36.1 million during Q1 2021.
  • Over the past 3 years, Arcutis Biotherapeutics' median Operating Expenses value was $80.9 million (recorded in 2024), while the average stood at $82.1 million.
  • In the last 5 years, Arcutis Biotherapeutics' Operating Expenses spiked by 84.79% in 2022 and then dropped by 28.88% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Operating Expenses (Quarterly) stood at $71.3 million in 2021, then climbed by 0.14% to $71.4 million in 2022, then climbed by 4.64% to $74.7 million in 2023, then grew by 5.75% to $79.0 million in 2024, then increased by 8.20% to $90.7 million in 2025.
  • Its Operating Expenses was $90.7 million in Q3 2025, compared to $96.1 million in Q2 2025 and $90.4 million in Q1 2025.